Factors affecting overall survival in early-onset gastroenteropancreatic neuroendocrine tumours (GEP-NETs): A multicenter database study using TriNetX.

D Deevyashali Parekh (2SUNY Upstate University, Department of Internal Medicine, Syracuse, United States) A Ansy Patel (2SUNY Upstate University, Department of Internal Medicine, Syracuse, United States) D Devashish Desai (1SUNY Upstate Medical University, Hematology and Oncology, Syracuse, United States) A Anupa Rani Mandava (SUNY Upstate Medical University, Syracuse, NY) A Ayushi Shah (SUNY Upstate Medical University, Syracuse, NY) N Nour Sabiha Naji (SUNY Upstate Medical University, Syracuse, NY) E Eloho Olojakpoke (Suny Upstate Medical University, Syracuse, New York, United States) O Osama Batayneh (1SUNY Upstate Medical University, Hematology and Medical Oncology, Syracuse, United States) R Rahul Seth (1SUNY Upstate Medical University, Syracuse, United States)

Abstract

626 Background: The incidence of early-onset gastroenteropancreatic neuroendocrine tumors (EO GEP-NETs), defined as diagnosis before age 50, is on the rise. Given their heterogeneous disease course, we aimed to identify clinical and demographic factors associated with overall survival (OS) in this population. Methods: We conducted a multicenter retrospective study using the TriNetX research platform, a federated network of de-identified electronic medical records. Adults diagnosed with EO GEP-NETs between January 1 st 2010 and January 1 st 2025 were identified, and effect of covariates on OS was evaluated using Cox proportional hazards model. Covariates included age at index, sex, race, marital status, obesity, type 2 diabetes mellitus, nicotine and alcohol dependence, depression, and metastatic sites (liver, bone, peritoneum, brain, lymph nodes, lung, retroperitoneum). Results: A total of 17,476 patients with EO GEP-NETs were identified; 42.3% were female and 65.3% were white. Factors associated with worse prognosis and increased mortality included male sex [HR 1.35, 95% CI 1.24–1.46; p<0.0001], nicotine dependence [HR 1.35, 95% CI 1.19–1.54; p<0.0001], type 2 diabetes mellitus [HR 1.21, 95% CI 1.05–1.39; p=0.008], and older age at diagnosis [HR 1.02 per year, 95% CI 1.02–1.03; p<0.0001]. Metastatic sites significantly associated with worse OS included liver [HR 2.53, 95% CI 2.18–2.93; p<0.0001], bone [HR 2.41, 95% CI 1.95–2.97; p<0.0001], peritoneum [HR 2.27, 95% CI 1.81–2.84; p<0.0001], brain [HR 2.23, 95% CI 1.69–2.94; p<0.0001], lymph nodes [HR 2.05, 95% CI 1.74–2.41; p<0.0001], and lung [HR 1.68, 95% CI 1.33–2.11; p<0.0001]. Protective factors included obesity [HR 0.84, 95% CI 0.74–0.96; p=0.01] and "married" status [HR 0.73, 95% CI 0.66–0.81; p<0.0001]. Race, alcohol dependence, and depression were not significantly associated with OS. Conclusions: Among patients with EO GEP-NETs, adverse prognostic factors include male sex, nicotine dependence, type 2 diabetes, older age at diagnosis, and metastatic involvement of the liver, bone, peritoneum, brain, lymph nodes, or lung. In contrast, marital status and obesity were associated with improved survival. These findings highlight prognostic heterogeneity in EO GEP-NETs and may help inform risk stratification and patient counseling. Cox proportional hazard model for overall survival. Covariate Hazard ratio P value 95% confidence interval Male 1.345 <0.0001 (1.238, 1.462) Alcohol dependence 1.033 0.862 (0.718, 1.486) Nicotine dependence 1.354 <0.0001 (1.189, 1.541) Overweight and obesity 0.843 0.010 (0.740, 0.961) Married 0.731 <0.0001 (0.660, 0.809) Depression, unspecified 0.838 0.118 (0.671, 1.046) Type 2 diabetes mellitus 1.209 0.008 (1.052, 1.389) Age at Index 1.021 <0.0001 (1.015, 1.026)

Article Details

Volume / Issue Vol. 44, Issue 2_suppl
Published January 10, 2026
Pages 626-626
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (9)

D

Deevyashali Parekh

2SUNY Upstate University, Department of Internal Medicine, Syracuse, United States

A

Ansy Patel

2SUNY Upstate University, Department of Internal Medicine, Syracuse, United States

D

Devashish Desai

1SUNY Upstate Medical University, Hematology and Oncology, Syracuse, United States

A

Anupa Rani Mandava

SUNY Upstate Medical University, Syracuse, NY

A

Ayushi Shah

SUNY Upstate Medical University, Syracuse, NY

N

Nour Sabiha Naji

SUNY Upstate Medical University, Syracuse, NY

E

Eloho Olojakpoke

Suny Upstate Medical University, Syracuse, New York, United States

O

Osama Batayneh

1SUNY Upstate Medical University, Hematology and Medical Oncology, Syracuse, United States

R

Rahul Seth

1SUNY Upstate Medical University, Syracuse, United States